Results from a Phase 1b Study of UCB0599, an Orally Available, Brain-penetrant Inhibitor of Alphasynuclein (ASYN) Misfolding in People Living with Parkinson's Disease (PD)
NEUROLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
NEUROLOGY(2021)